中国生物制药（01177）今日盘中大涨7.15%，截至14:32，股价创下近期新高。该股价的强劲表现主要得益于公司近期发布的积极业绩报告以及新产品获批上市的利好消息。
根据中信建投证券的研报，中国生物制药2025年上半年实现营收175.7亿元，同比增长10.7%；归母净利润33.9亿元，同比增长140.2%。公司的创新产品表现强劲，特别是普坦宁（美洛昔康注射液）和安启新（注射用重组人凝血因子VIIa）相继获批上市，为公司带来新的增长动能。
值得注意的是，中国生物制药未来三年（2025-2027年）预计将有近20款创新产品陆续获批上市，其中超半数为峰值销售额有望突破人民币20亿元的重磅品种。这一产品管线的强劲表现，加上整体生物科技板块的上涨趋势，共同推动了公司股价的显著上涨。分析师普遍认为，随着公司创新产品收入占比的提升和新产品的持续获批，中国生物制药有望保持稳健的增长态势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.